When many people come to Cancer Treatment Centers of America® (CTCA), they are looking for a solution that meets their unique needs. CTCA is a specialized health care company that operates with a philosophy that each patient is unique, and deserves a comprehensive approach to their treatment, that takes not only their own unique health issues in mind but also relies on the most recent cancer treatment data.
That’s why CTCA has partnered with NantHealth and Allscripts to create a custom solution while helping eviti®, another NantHealth clinical decision support solution, to access clinical workflows in the Allscripts Sunrise electronic health record.
What does this mean in a practical, everyday sense? Treatment decisions will come faster. The Clinical Pathways program helps inform the cancer treatment process, without interrupting the physician’s clinical workflow, providing a clinical decision support solution that is both practical and cutting-edge.
The project to improve the workflow came from a practical source as well: A network of hundreds of oncologists across the US. The direct interface of the clinical operating system (NantOS) was crowds ourced and built with their input. With this expertise, Cancer Treatment Centers of America has access to a comprehensive collection of cancer data to use for critical clinical decisions.
Every cancer is as unique as the person fighting it, and that’s why fighting cancer requires truly personalized care, delivered by experts trained in the complexities of a difficult disease. This data will help doctors at CTCA continue to offer the best medical care to their clients, based on the most recent data in the field.
Dr. Clay Siegall is the co-founder of a renowned biotechnology company, Seattle Genetics. He has made significant contribution in the industry by researching on cancer therapies. His involvement in the field of cancer therapy was inspired by his painful experience of losing his father to cancer. In the past, the field of oncology had limited resources. Clay studied Genetics at the George Washington University with the objective of improving the situation. For thirty years, Clay has spent each day working towards developing viable cancer treatments. He believes in staying informed through learning and interacting with different experts. Clay enhances the growth of Seattle Genetics by partnering with other players in the industry. Through this strategy, he has managed to advance the company’s ADC technology by investing in new ideas to help treat cancer.
About Clay Siegall
Clay Siegall serves as the president and CEO of Seattle Genetics. He is also the chairman of the board. Seattle Genetics is run on the foundation of scientific innovation, in-depth research and drug development practices. These elements have contributed to the success of the company. Seattle Genetics is a leader in the development of Antibody-drug conjugates. Clay enabled the company to secure FDA’s approval in 2011 for ADCETRIS. The company has collaborated with Takeda Pharmaceutical Company to sell ADCETRIS in more than 65 countries. In addition, Clay Siegall has made much success with Seattle Genetics. He has played a pivotal role in advancing a diverse pipeline of ADCs, securing multiple strategic licenses for ADC technology with several companies, and funding the company’s activities. Recently, he raised over $1.2 billion.
Previously, he worked for Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and National Institutes of Health. Presently, he serves on the boards of Directors of Alder BioPharmaceuticals, Washington Roundtable and Ultragenyx Pharmaceutical. He is a recipient of several awards, including the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. In 2012, he received the Pacific Northwest Ernst & Young Entrepreneur of the Year. Clay holds 15 patents. In addition, he has authored over 70 publications. Clay graduated with a B.S. in zoology from the University of Maryland.
In the past there has always been limited communication between an inmate and their loved ones. Now that technology is growing at a rapid rate and becoming more accessible prisons can use it to allow more supervised and safe communications outside the prison walls.
Securus Technologies is a leading provider in criminal justice technology accessories for all public safety offices, prisons, and correctional facilities. The company offers a lot of technology to help prevent inmate on inmate crime. A number of inmates and employees at these secured facilities have only had positive things to say about what Securus Technologies has created.
The company is working so hard so that they can keep producing and updating products once every week. There have been over a thousand positive comments from families explaining how much the new technology has helped improve communication with loved ones and keep everyone safe. Securus Technologies is built off of the principles of safety.
Here are some letter examples:
I was able to track down a corrupt security guard by recovering information from his cell phone. After getting the warrant the man was arrested and relieved of his duties. A big shout out to Securus Technologies and all their hard work.
Several calls between inmates about alcohol use, drug selling and drugs were recorded. All of the inmates involved were approached and handled with discipline.
Our company has relied on Securus Technologies for ten years now and have never had a problem. It is great having a partnership with a company that is continuously adding innovative products to revolutionize the market.
I am really liking the vision of Securus Technologies. The development and increased capabilities of their products continues to make security stronger.
All the tools have helped our facility easily conduct investigations when there are complaints of fights, abuse, drugs, etc.
Mikhail Blagosklonny is considered one of the greatest additions in the field of Cancer research. Besides authoring several research essays that have been quoted severally in journals and by fellow scientists Mikhail is also the brains behind new waves or cancer treatments that protect normal body cells.
Mikhail Blagosklonny attained his MD in Internal Medicine at the First Pavlov State Medical University of St. Petersburg. He later pursued his PhD in the same university, specializing in the fields of experimental medicine as well as cardiology. Through his written works, Mikhail Blagosklonny has earned a lot of recognition among his fellow scholars and scientists, who popularly know him as Misha.
After completing his studies, Mikhail Blagosklonny took a job as an associate professor or medicine at the New York Medical College. He spent a few years there before finding a new opportunity for scientific research at the Ordway Research Institute. It is here that Mr Blagosklonny discovered his passion in research, specifically on the fields of cancer biology and oncology.
Mikhail’s inquisitive nature saw him diversify his research work in a quest to answer the many cell biology puzzles that boggle many oncologist minds. Misha has written extensively on many topics among them, molecular and cellular biology, cell cycle, clinical investigations, cellular senescence and signal transductions. Under the topic of transduction, Mikhail went deeper into studying the aging process on nature.com. His discoveries were profound, and for the first time oncologists believed that slowing down the aging process gradually slows down cancer growth and any age related diseases.
It is in 2009 that Blagosklonny joined the Roswell Park Cancer Institute as a professor or oncology. He joined the research center at an opportune time when his ideologies were in line with those of fellow oncologists at the center. At the core of cancer therapy on impactjournals.com, Mikhail believes in the importance of cell protections against the adverse effects of radiology and chemotherapy. Blagosklonny is also instrumental in unearthing newer combinations of cancer treatment drugs that not only protect the body’s normal cell biology but also lower the side effects of common cancer drug cocktails.
Mikhail believes the human body can fight cancer without over reliance of medication at https://en.wikipedia.org/wiki/Mikhail_Blagosklonny. This is why he has dedicated his career into discovering fresh concepts in cancer biology and cancer therapy. Mikhail strongly believes the answer is in slowing down the aging process which ultimately lowers the onset of cell tumors.
Among leading law firms in the U.S., Labaton Sucharow remains top of on chart due to the kind of services they offer. They not only work with attorneys and professionals with legal experience, but have a team of professionals in other specialties as well, who review the cases presented and make the process of resolving issues easier. The company has remained strong for over 50 years and their projects have been helping individuals, businesses and institutional investors.
One of the most notable steps that Labaton Sucharow made in the recent past is the inclusion of a service that supports whistleblowers by exposing them to the legal framework that governs the SEC Whistleblower Program. The company offers advice and support that allows whistleblowers to come out with facts that can lead to a successful pursuit of violations through the SEC.
As a reward to their effort, one of the clients they worked with won a reward amounting to over $17 million issued by the SEC for revealing details about the violations that have existed for years in the financial services industry. The client followed up on the case through Labaton Sucharow and tried to expose individuals who have for many years troubled progress. Few would have taken the step but the whistleblower in this case went ahead without fear and exposed the violations.
As a SEC Whistleblower attorney explains, the case highlighted here is a show of bravery and it is expected more such individuals will emerge to expose the things that have been happening in different industries. Labaton Sucharow is also hopeful that they will continue to provide the required support to whistleblowers to ensure their cases are rewarded deservedly.
One of the biggest takeaways from the interview is that Josh Verne said that he wished he would have paid greater attention to the advice of those around him much sooner. It is too easy to ignore or dismiss the advice of subordinates or colleagues. This is especially true when you are the boss and people work for you says Josh Verne.
Paying attention to what others say can teach you a lot on how you can improve your business or product. It can also give you new insight into how you run your business that you may have never noticed before. A quote that Josh Verne threw out during the interview is that you have two ears and one mouth for a reason. It is so you can listen more than you talk. By following this “saying” you will learn a lot and realize a lot of new things.
Josh Verne also said to to be a truly successful leader instead of just a boss is that you must treat your employees with respect and earn their trust and respect. A boss commands and people listen to him because of their rank. A leader on the other hand is listened to because he or she values the opinion of those beneath them as well as their colleagues. By being a leader and team player you will be much more productive than if you were just a boss who sits in his office all day.
Josh Verne is a businessman who resides in the Philadelphia suburbs. He is married, has kids and says that spending time with his family is one of the most important things any father can do. His businesses include FlockU, a website that allows college students to share news, tips and help each other through the web.
Mr. Verne is also involved in the furniture business. He has warehouses that supply retailers in the Philadelphia metro area and beyond. Josh has also helped launch Work Pays Me, a financial payment company that helps employees receive pay directly.
People of wealth collect art for various reasons. Some see it as a hedge against economic downturn. They buy art as an investment rather that as objects of genius and beauty to display on their walls. These art collectors stick to the proven artists like Picasso, Rembrandt, and Gauguin whose limited works continue to appreciate in value regardless of the economy.
Other wealthy art collectors add to their collections simply because they appreciate the works of beauty. Pride of ownership, a desire to gather a noted collection for others to see and enjoy, and yes, ego, all are motives that drive these discerning collectors.
Then there is the art collector like Adam Sender. Over the past two decades, this highly successful fund manager has accumulated a collection of 1,000 pieces of art with an estimated value of over $100 million dollars. Sender’s strategy in collecting art came from his uncanny ability to recognize the potential value of companies and stocks. He approaches art collecting in much the same way.
You won’t find any of the grand masters in his collection. Sender prides himself in being able to recognize the potential of modern, working artists and purchase their works at low, beginning-artists prices in hopes their value will spiral upwards as the artist gains fame and followers.
For instance, he recognized the talent of a young artist names Cindy Sherman. He purchased one of her paintings for $100,000. It is now worth close to $4,000,000.
Sender was able to get other works from such artists as Richard Prince and Martin Kippenberger at bargain basement prices because he recognized their value long before the general market did.
is also noted for including many works of art by female artists such as the aforementioned Cindy Sherman. He calls these works by women hidden jewels of the art world.
He is also unusual as an art collector because he loves to share his work with others. Sender gladly loans his pieces to art museums and special exhibits. While many in the high stakes art collecting world tend to keep their works private and out of the public view, Sender relishes in letting outsiders view his works. He says letting others see his collection for the first reminds him of the thrill he got when he saw these pieces for the first time himself.
Sender has also proven to be a savvy seller when it came time to reduce the size of his collection. In 2006, he netted nearly $20 million on 40pieces sold at auction. Seeking to liquidate his art positions even further, he has recently engaged Sotheby’s auction house to move another 400 works by 139 artists over a period of 18 months.
Brazil has had numerous great writers but was not looked upon as a literary powerhouse because many of its inhabitants were illiterate. Modern times with better education and world wide access to the internet are changing that landscape. The following is only a snippet of authors who have and do impact the literary world from Brazil.
One famous Brazilian self-described story teller is Jorge Amado. His internationally bestselling books reflected Brazilian culture, focusing on inequalities among race and class. He was never averse to controversy but as he aged his writing took on a more humorous angle away from the earlier ideology. His books became transcribed into tv shows, operas and plays. Because of this he was originally snubbed by academics but loved by the populous. Amado died in 2001 and in 2012, Brazil celebrated his 100th birthday.
The best-selling Brazilian novelist of all time is Paulo Coelho. He first started out as a musician and songwriter but then went on to fulfill his dream of writing. His masterpiece The Alchemist, is considered a modern classic and is the most translated book of a living author. Still a vigorous writer his fan following can follow his daily blogs. He is the writer with the largest online community.
Bernardo Carvalho is a newer name in Brazilian literature. He like many others he began as a journalist. He worked in both Paris and New York and these experiences found their way into his narratives. He blends the different cultures and cultural reactions together. In his novel Nine Nights he weaves a backdrop describing the enormous changes in Brazil’s interior and the impact suffered by its natives while telling the tale of an American who kills himself and leaves seven letters as to why he did it.
An even newer name is Jamie Garcia Dias. He followed in his father’s footsteps as a writer and has spent time as a journalist. He has published twenty books, five of which have won awards. He has held prestigious positions in Brazilian literary organizations. With this, he is becoming one of the leading writers in Brazilian fiction literature. His major award winning novel Fell from Heaven has sold throughout all of South America. If this trend continues, Jamie Garcia Dias will most likely be familiar in North America soon.